An Effective Solution to Discover Synergistic Drugs for Anti-Cerebral Ischemia from Traditional Chinese Medicinal Formulae

Shaojing Li1,2, Chuanhong Wu1,1, Jianxin Chen2,3, Peng Lu1,1, Chang Chen1, Meihong Fu1, Jing Fang1, Jian Gao4, Li Zhu1,5, Rixin Liang1, Xin Shen1, Hongjun Yang1*
1 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China, 2 Information Center, Beijing University of Chinese Medicine, Beijing, China, 3 Institute of Automation, Chinese Academy of Sciences, Beijing, China, 4 College of Pharmaceutical Science, Hebei University, Baoding, Hebei, China, 5 Jiangxi University of Traditional Chinese Medicine of pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China

Abstract

Recently, the pharmaceutical industry has shifted to pursuing combination therapies that comprise more than one active ingredient. Interestingly, combination drug therapies have been used for more than 2500 years in traditional Chinese medicine (TCM). Understanding optimal proportions and synergistic mechanisms of multi-component drugs are critical for developing novel strategies to combat complex diseases. A new multi-objective optimization algorithm based on least angle regression-partial least squares was proposed to construct the predictive model to evaluate the synergistic effect of the three components of a novel combination drug Yi-qin-ji-du formula (YJ), which came from clinical TCM prescription for the treatment of encephalopathy. Optimal proportion of the three components, ginsenosides (G), berberine (B) and jasminoidin (J) was determined via particle swarm optimum. Furthermore, the combination mechanisms were interpreted using PLS VIP and principal components analysis. The results showed that YJ had optimal proportion 3(G):2(B):0.5(J), and it yielded synergy in the treatment of rats impaired by middle cerebral artery occlusion induced focal cerebral ischemia. YJ with optimal proportion had good pharmacological effects on acute ischemic stroke. The mechanisms study demonstrated that the combination of G, B and J could exhibit the strongest synergistic effect. J might play an indispensable role in the formula, especially when combined with B for the acute stage of stroke. All these data in this study suggested that in the treatment of acute ischemic stroke, besides restoring blood supply and protecting easily damaged cells in the area of the ischemic penumbra as early as possible, we should pay more attention to the removal of the toxic metabolites at the same time. Mathematical system modeling may be an essential tool for the analysis of the complex pharmacological effects of multi-component drug. The powerful mathematical analysis method could greatly improve the efficiency in finding new combination drug from TCM.

Introduction

The mainstream international medical community recognizes that single-constituent and single-target drugs are limited. The success of cocktail therapy, which represents multicomponent anti-AIDS drugs, has stimulated people’s interest in combination drugs [1]. Combination drugs that simultaneously impact multiple targets are more effective in controlling complex disease systems, such as stroke, than drugs designed to act against individual molecular targets [2]. The complexity of medicine suggests that treatment protocols should be carefully designed; prescription construction in combination drugs is an art to fight disease. Traditional Chinese medicine (TCM) is one of the few rare ancient traditional techniques still widely practiced that holds systematic theories to prevent and therapy diseases. To enhance therapeutic efficacy and reduce adverse effects, practitioners of TCM prescribe a combination of plant species and/or minerals, called formulae, based on their clinical experience. Nearly 100,000 formulae have been recorded; however, the mechanism of action for most remain unknown [3]. It is believed that, at least in some formulae, multiple components affect multiplex targets and exert synergistic therapeutic efficacies. In 2008, Chen et al succeed in explaining the combination mechanisms of Realgar-Indigo naturalis formula, which had been proven to be very effective in treating human acute promyelocytic leukemia [3]. However, the optimal proportions and precise mechanisms of most formulae remain unidentified. Thus, the concerns listed above have hampered the development of TCM. Traditional statistical methods have limitations in the process to deal with complex relationship of formulae. It is
Understanding optimal drug proportions and synergistic mechanisms of multicomponent drugs are critical for developing novel strategies to cope with complex diseases. It is believed that combinations of agents can effectively reduce side effects and improve adaptive resistance, and in that way, it is able to increase the probability of fighting complex diseases, such as stroke, in a synergistic manner [31]. Mathematical system modeling may be an essential tool for the analysis of the pharmacological effects of multi-component drug to highlight the complex relationship between drugs and their targets, which are characterized as a small sample size and the dispersed, nonlinear data, but until now its application is still limited and the successful case is rare in this area. It was prospected that this study would lay foundation to scientific analysis and evaluation of the complex interaction of the multicomponent and further clarify the nature of combination drug via the dissection of YJ in this paper.

Materials and Methods

2.1 Animals

Adult male Sprague–Dawley rats weighing 250–270 g were obtained from the Animal Breeding Center of the Beijing Vital River Laboratories Company (Beijing, China). All animals were individually housed at 22±2°C with a relative humidity of 50±10% and a 12 h light/12 h dark cycle. The animals had free access to food and water. The experimental procedures were approved by the China Academy of Chinese Medical Science’s Administrative Panel on Laboratory Animal Care. All animal
experiments were performed in accordance with institutional guidelines and ethics.

2.2 Chemicals and Reagents

Ginsenosides (Rg1=Re+Rd+Rb2+Rb1+F1+F2+Rc+Rg3 = 82.62 ± 2.98%), see Table S3, S4, and S5, Figure S1–S26) was purchased from Nanjing ZeLang Medical Technology Co., Ltd (Nanjing, China). The ginsenosides standards for ginsenoside Rb1 (Rb1), ginsenoside Rb2 (Rb2), ginsenoside Rb3 (Rb3), 20(S)-ginsenoside F1 (F1), 20(S)-ginsenoside F2 (F2), ginsenoside Rg1 (Rg1), ginsenoside Rg3 (Rg3), ginsenoside Re (Re), ginsenoside Rb1 (Rb1), ginsenoside Rd (Rd) were purchased from National Institutes for Food and Drug Control (Beijing, China). Methanol and acetonitrile were purchased from Thermo Fisher Scientific Inc. (Iowa, USA). Berberine (Purity ≥95.18%) was purchased from Xianyang Aviation 168 Bio-engineering Co., Ltd (Xianyang, China). Jasminoidin (purity ≥99.68%) was purchased from Baoji F.S. Biological Development Co., Ltd (Baoji, China). EGb761 was purchased from Dr. Willmar Schwabe (Karlsruhe, Germany). Resazurin sodium salt, 2, 3, 5-triphenyltetrazolium chloride (TTC), 1,6-diphenyl-1,3,5-hexatriene (DPH), rhodamine 123, paraformaldehyde, glutaral, osmic acid, propylene oxide, resin, uranyl acetate and lead citrate were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Rabbit polyclonal anti-Bax (P-19) and anti-active caspase-3 antibodies and mouse monoclonal cytochrome c (A-8) and b-actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Bcl-2 (50E3) was purchased from Cell Signaling Technology (Beverly, MA, USA). The JC-1 (lipophilic cation 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 3′-tetrathyl-benzimidazol-carb-oxyanide iodide) Mitochondrial Membrane Potential Detection Kit was purchased from the Beyotime Institute of Biotechnology (Haimen, China). The BCA Protein Assay Kit and the Super ECL plus Western Blotting kit were purchased from Life Technologies (Carlsbad, CA, USA).

2.3 Animal models and experimental design

After 48 h of acclimatization, rats were anesthetized with chloral hydrate at a dose of 400 mg·kg⁻¹ (i.p.). Rectal temperature

![Figure 1. The therapeutic effects of YJ with the optimal proportion.](image-url)

(A)–(C) Effects of YJ on neurological deficits, cerebral infarct volume and content of cerebral water in rats induced by MCAO. EGb761 and YJ were both administered i.g. 15 min prior to MCAO and 6 h after MCAO. (D-1) Detection of cerebral blood flow. The cerebral blood flow perfusion color image [D-1. a (1–5) and c (1–5)], detected position image [D-1. b (1–5)], and blood flow time window [D-1. d (1–5)] are presented. [1, Vehicle control; 2, EGb761-treated group; 3–5, YJ-(1,5 and 25 mg·kg⁻¹) treated group; (D-2) The reduced rate of rCBF. EGb761 and YJ were both administered i.g. 15 min prior to MCAO. Values were expressed as the mean ± SD (A, B and C, n = 10; D, n = 5), and the data were analyzed by one-way ANOVA. **P < 0.01, *P < 0.05 versus the sham group; **P < 0.01, *P < 0.05 versus the vehicle control. doi:10.1371/journal.pone.0078902.g001
was recorded and maintained at 37 ± 0.5°C throughout the surgical procedure. The middle cerebral artery occlusion (MCAO) operation by the intraluminal filament method was performed according to a slightly modified previously reported method [32]. Briefly, a 4-0 monofilament nylon suture with a round tip was inserted from the left external carotid artery into the lumen of the internal carotid artery to occlude the origin of the MCA. The rats were sacrificed at 12 h or 24 h after the MCAO procedure.

To dig into the optimal proportions of ingredients in the YJ, the rats were randomly divided into nine groups according to a uniform design (n = 10/group, Table 1). Each group was administered YJ intragastrically (i.g.) 6 h after MCAO; the related indices of mitochondrial function were assayed 24 h after MCAO.

To study the anti-cerebral ischemia effect of YJ, rats were randomly divided into the following 6 groups (n = 10/group): sham group; vehicle control group; positive control EGB761 group (4 mg kg⁻¹); and YJ-treated groups (1, 5 and 25 mg kg⁻¹). YJ was dissolved in physiological saline to make the stock solution. Dilutions were then prepared for administration of different dosages. YJ and the positive control, EGB761, were administered intragastrically 15 min prior to MCAO (PM) and 6 h after MCAO (AM). The sham and vehicle-treated rats were administered physiological saline intragastrically. Neurological defects were determined at 12 h and 24 h after MCAO followed by an examination of the cerebral infarct volume. The entire brain or cortex was then removed and processed to detect cerebral infarct size, cerebral edema and mitochondrial function. Regional cortical blood perfusion was also determined. Based on the data from the uniform design and pharmacological experiment, a synergistic experimental design (n = 10/group) was proposed to further

![Figure 2. The construction of the predictive model for YJ.](https://example.com/figure2)
investigate the mechanisms of the YJ. Each group was administered treatment intragastrically 6 h after MCAO, and the related indices of mitochondrial function were assayed at 24 h after MCAO.

2.4 Uniform experimental design

To explore the optimal proportions of the YJ, a new experimental design method named uniform design was used. This method may potentially overcome the drawbacks of orthogonal designs [33,34]. This method seeks to design points to be uniformly scattered in the experimental domain [34]. The main difference between the uniform design and the orthogonal design is that the uniform design ensures that there is an experiment is conducted for each factor in each level once only. Consequently, this method can significantly reduce the number of experiments. The uniform design, like the orthogonal design, can be tabulated. It uses a uniform table to organize the factors and levels of each factor. The table is represented as Un(qs), where U represents the uniform design, n is the number of experiments, q is the number of levels, and s is the maximum number of factors. The detail of the uniform design of the YJ is shown in Table 1.

For the uniform design, the experimental design process was as follows:

1. Determining the factors and number of levels.
2. Choosing an appropriate table to accommodate the number of factors and levels.
3. Conducting the experiments indicated in the table to collect data on the effect on the performance measure.
4. Completing data analysis to find a suitable model to fit the data.
5. Determining the optimal factor combinations, or discover information built into model.

2.5 Preparation of rat brain mitochondria

Rat brain mitochondria were isolated from the left cortical tissue 24 h after the MCAO procedure. Forebrain tissue was quickly removed and placed in ice-cold isolation buffer (250 mM sucrose containing 10 mM Tris- HCl, 0.5 mM Na2EDTA and 0.1% BSA, pH 7.1). The tissue was then washed to remove redundant blood and homogenized [20% (w/v)]. Cellular nuclei and cell debris were sedimented by centrifugation at 600 rpm for 3 min and 1000 rpm for 5 min and then discarded. The supernatant was subjected to further centrifugation at 10,000 rpm for 8 min. The mitochondrial pellet was washed by gently resuspending the pellet in isolation medium and then centrifuging at 10,000 rpm for 8 min [35]. Finally, the mitochondria were resuspended in the above buffer to obtain a concentration of 10 mg/ml. All procedures were performed at 4°C. The mitochondrial protein concentration was determined via BCA assay.

2.6 Measurement of mitochondrial viability (Resazurin)

Resazurin is a sensitive indicator of mitochondrial function, which is hydrolyzed to fluorescent resorufin by enzymatic action related to mitochondrial activity [36]. Mitochondria (50 μg protein) were added into a 96-well plate and incubated with 5 μM resazurin at 37°C. Fluorescence intensity was measured after one hour of incubation using a microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA) set to an excitation wavelength of 530 nm and emission wavelength of 590 nm. Samples containing equal amounts of mitochondrial protein that had been heated to 100°C for 10 min prior to the addition of resazurin were used to obtain the background signal. Greater fluorescence intensity of resorufin indicated better resultant mitochondrial viability.

2.7 Measurement of mitochondrial swelling (PT)

Mitochondrial swelling following PT pore opening was assayed by measuring the reduction in absorbance at 520 nm at 25°C, according to the method used by Tian [37]. The turbidity of the reaction mixture reflected the degree of mitochondrial swelling. The assay mixture contained freshly prepared mitochondrial protein (50 μg protein), 70 mM sucrose, 10 mM succinate, 5 mM Hepes, 1 mM Na2HPO4, 210 mM mannitol, 2.7 μM rotenone, and 1 μg·ml−1 oligomycin A (pH 7.4). A kinetic decrease in absorbance was recorded over a period of 10 min in 200 μl medium using the microplate reader described above. The control group had the same amount of mitochondria without rotenone and oligomycin A. The detected absorbance had a good linear relationship and the absolute slope was used to compare each group. Steeper slopes indicated greater mitochondrial swelling [38].

2.8 Measurement of Mitochondrial Membrane fluidity (FP)

Membrane fluidity was measured by the fluorescence polarization (FP) method using diphenylhexatriene (DPh) as a probe, as previously described by Hirano [39]. DPh (5 μM) was added to freshly prepared mitochondria in medium (250 mM sucrose containing 10 mM Tris-HCl, 0.5 mM Na2EDTA and 0.1% BSA, pH 7.1), which were incubated at 37°C for 30 min to allow probe incorporation. The mp value was monitored at 37°C with the microplate reader described above. The excitation wavelength was 362 nm, and the emission wavelength was 432 nm. To identify the effect of YJ, η, which represents the coefficient of viscosity of the mitochondrial membrane, was calculated according to the formula:

\[
\eta = 2P/(0.46 - P)
\]

Where the values of P were calculated using the formula P = 1000 × mP. Greater values of η indicated reduced fluidity of the mitochondrial membrane.

| Table 3. Optimal composition and target values. |
|----------------------------------------------|
| Ginsenosides | Berberine | Jasminoidin | Resuzurin | FP | JC1 | PT | Rho |
|---------------|-----------|------------|-----------|----|-----|----|-----|
| Ginsenosides  | Berberine | Jasminoidin | Resuzurin | FP | JC1 | PT | Rho |
| 4.4205        | 2.9546    | 0.8669     | 429.8514  | 4.0134 | 24.6169 | 0.1190 | 104.0423 |

[DOI:10.1371/journal.pone.0078902.t003]
2.9 Measurement of Mitochondria Transmembrane Potential (MMP, ΔΨm)

2.9.1 Rhodamine 123 Method (Rho). Changes in brain mitochondrial ΔΨm were measured in the presence of rhodamine 123 (Rh123) as described previously [40]. The excitation and emission wavelengths for Rh123 were 503 and 527 nm, respectively, using a SpectraMax M5 Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). Mitochondrial ΔΨm was assessed based on the quantitation of Rh123 quenching. Low ΔΨm levels corresponded to greater Rh123 fluorescence. The basal fluorescence (ΔΨm) total) was determined before adding mitochondria.

2.9.2 JC-1 Method (JC1). As another method, the JC-1 Mitochondrial Membrane Kit (Beyotime Institute of Biotechnology, Haimen, China) was also used to monitor changes in ΔΨm. JC-1 is an ideal fluorescent probe for the detection of ΔΨm. When ΔΨm is high, JC-1 aggregates in the matrix of the mitochondria, producing red fluorescence. By contrast, when ΔΨm is low, JC-1 exists in its monomeric form and produces green fluorescence. The ratio of the red to green fluorescence intensity at 590 nm compared to that at 530 nm was used to measure depolarization of the mitochondrial membrane [42].

2.10 Data Analysis

2.10.1 Data Preprocessing. It was necessary that some data preprocessing steps were prior to analysis to reduce or eliminate any outliers, missing values, or bad data points, and ensure that the data were perfectly suitable for modeling [43,44]. Normalization procedures were applied to meet these challenges for integrated data analysis. All of the data of mitochondrial function from the uniform design experiment was divided by two groups: a factor group and an indexed group. The factor group had 9 rows and 3 columns (X9×3), and the indexed group had 9 rows and 5 columns (Y9×5). Each group was transformed the mean and standard deviation of each column to 0 and 1. The mapping function was as follows:

\[
norm_{ij} = \frac{v_{ij} - \text{mean}_j}{\text{std}_j}
\]

Where \(v_{ij}\) was the original value of \(X_{9 \times 3}\) or \(Y_{9 \times 5}\), \(\text{mean}_j\) was the mean of column \(j\), and \(\text{std}_j\) denoted the standard deviation of column \(j\).

2.10.2 LARS-PLS. Multi-target regression was a common issue in regression analyses [45]. In cases where samples are small, namely in the fields of medicine, the military field and chemical processes [46], the prediction becomes difficult. Some popular methods [47] do not attempt to fit data in small sample cases. Here, we proposed a method, named Least Angle Regression-Partial Least Squares to model these cases.

This method included two main parts: a Least Angle Regression algorithm [40] and a Partial Least Squares algorithm [49]. The Partial Least Squares algorithm applied well to small sample cases, while the Least Angle Regression algorithm added non-linear factors and improved fitting accuracy. This method may copy with two major problems in small sample cases. The first problem referred to multicollinearity in the independent variables [50]; the second problem relating to the number of samples was less than the number of variables [51].

Next, we introduced this procedure to one medical case. In this case, we needed to fit the regression model between drug components and efficacy indices. The procedure was illustrated as follows:

1. Choosing drug components as the independent variables and efficacy indices as the dependent variables, according to the actual medical situation.
2. Setting ratios of the drug components in experiments according to principles of uniform design. Recording the efficacy indices of each experiment.
3. Assigning the experimental data to independent variables and dependent variables, and forming the independent variable and dependent variable matrices. In the independent matrix, each row corresponds to the component ratio in each drug experiment, and each column corresponds to one drug component. In the dependent matrix, each row corresponds to each efficacy index of drug experiment, and each column corresponds to one efficacy index.
4. Expanding the independent matrix to add nonlinear factors. As to each row, calculate the quadratic value between each component index in turn. Add the quadratic values of each sample to the end of corresponding row. In this way, the new independent matrix is established.
5. Applying the Partial Least Squares algorithm to retrieve principle components. Firstly, set the number of principle components as ncomp, and retrieve useful information from the

Table 4. The mitochondrial function index of the verification experiment.

| Group       | Dose (mg kg⁻¹) | n  | Reasurin   | PT  | FP  | MMP |
|-------------|----------------|----|------------|-----|-----|-----|
|             |                |    |            |     |     | Rho | JC1 |
| Sham        | -              | 10 | 531.33 ± 152.53 | 0.152 ± 0.012 | 3.67 ± 0.30 | 131.53 ± 2.23 | 26.58 ± 1.49 |
| Vehicle     | -              | 10 | 330.28 ± 61.42  | **0.678 ± 0.011** | **5.89 ± 3.11** | **125.17 ± 4.70** | **21.80 ± 3.44** |
| EGb761      | 4              | 10 | 427.20 ± 87.05  | **0.276 ± 0.021** | **3.70 ± 0.49** | **129.92 ± 3.98** | **24.68 ± 2.69** |
| YJ          | 1              | 10 | 377.02 ± 109.08 | **0.269 ± 0.010** | **4.03 ± 0.47** | **127.05 ± 2.56** | **22.01 ± 2.03** |
| YJ          | 5              | 10 | 440.92 ± 75.89  | **0.164 ± 0.008** | **3.74 ± 0.55** | **130.20 ± 3.04** | **21.88 ± 0.84** |
| YJ          | 25             | 10 | 481.91 ± 69.99  | **0.159 ± 0.007** | **3.49 ± 0.51** | **129.44 ± 2.41** | **24.67 ± 1.94** |

Values were expressed as the means ± SD (n = 10) and the data were analyzed by one-way ANOVA, **P < 0.01, *P < 0.05 versus the sham group, **P < 0.01, *P < 0.05 versus the vehicle control. doi:10.1371/journal.pone.0078902.t004
the new independent matrix through projecting the independent matrix to the scoring matrix, in which the number of rows is the number of samples and the number of columns is ncomp. Similarly, project the dependent matrix to the scoring matrix. Build the PLS regression model between these two scoring matrices.

(6) Finally, projecting the principle components to the original variables in the reverse direction and obtain the regression model between drug components and efficacy indices.

Following these procedures, we were able to produce regression models for multiple targets in small sample cases. Moreover, given a set of drug components, this model could be used to predict efficacy indices.

To seek the optimal proportion of YJ, particle swarm optimization (PSO) was proposed. PSO has become a popular evolutionary algorithm in recent years, based on stochastic optimization techniques developed by Dr. Eberhart and Dr. Kennedy in 1995, which were inspired by social behavior research of bird flocking or fish schooling [52,53].

In PSO, the system is initialized with a swarm of random solutions, called particles in the problem space, and the system searches for optima by updating generations. Each of the particles refers to a fitness value associated with the optimal function and velocity determining the direction and distance of each particle. It also keeps track of the coordinates of the current best solution previously achieved. During each time step, the particle is updated by tracking two extreme values. One, called the personal-best (pbest), is the best solution the current particle has achieved so far. The other, called the global-best (gbest), is the best solution the entire swarm has encountered so far, which is continually updated by comparison with pbest values. If a current particle has reached a better optimization location, gbest will be updated and the next particle in the swarm will try to make its way towards the gbest location. In past several years, PSO has been successfully applied to many areas of research and application [44]. PSO has also been demonstrated to obtain better results in a method that is both faster and cheaper than other methods.

2.11 Pharmacological effects study for YJ under the optimal proportion

2.11.1 Assessment of neurological defects. To reveal the effect of YJ the neurological defects caused by the MCAO operation, neurological defects were determined by a single researcher at 12 h and 24 h after MCAO. The researcher was blinded to the experimental treatment groups. The neurological behaviors were scored on the following 5-point scale as described previously [54].

2.11.2 Cerebral infarct size. Cerebral infarct volumes were measured with TTC staining and used to describe the severity of cerebral ischemia. At 12 h and 24 h of ischemia, brains were quickly removed and sliced into 6 2-mm thick coronal sections. Brain slices were treated with 2% TTC saline solution and incubated at 37.5°C for 30 min, followed by 10% formalin fixation overnight, according to a previously described method [55]. After staining with TTC, normal tissue was stained a rose red color, and the infarct tissue was stained white. The images of the stained slices were photographed and recorded. The adjusted infarct areas and bilateral hemispheric areas of each slice were determined using an image analysis system (Image-pro plus 6.0). The infarct volume of each slice was calculated as the infarct area \( \times \) thickness (2 mm). The summation of the infarct volumes of all brain slices was recorded as the total infarct volume.

Figure 3. Effects of the anti-apoptotic effect of YJ with the optimal proportion. (A). Representative Western blots of Bcl-2, Bax, Cytochrome c, caspase-3 and \( \beta \)-actin. (B), (D), (E), The quantified densitometric analysis of Bcl-2, Bax, cytochrome c and caspase-3. (C). The ratio of Bax/Bcl-2 proteins. Values were expressed as the mean \( \pm \) SD for the four independent experiments, and the data were analyzed by one-way ANOVA. *\( P < 0.05 \), **\( P < 0.01 \) versus the vehicle control. doi:10.1371/journal.pone.0078902.g003
2.11.3 Evaluation of cerebral edema. Following decapitation at 12 h and 24 h after MCAO, the left cerebral hemispheres were obtained as described above and immediately weighed to obtain the wet weight. The tissue was then dried in an oven at 120°C for 24 h and then reweighed to obtain the dry weight. Cerebral water content [56] was calculated according to the following formula:

$$\text{Content of cerebral water} = \frac{(\text{wet weight} - \text{dry weight})}{\text{wet weight}} \times 100\%.$$ 

2.11.4 Regional cortical blood perfusion. Laser speckle contrast imaging (LSCI) is a technique based on speckle contrast analysis that provides an index of blood flow [57–59]. A reduction in rCBF plays an essential role in ischemia-induced brain injury. To evaluate the effect of YJ, rCBF was measured before and after MCAO for each group. After deep anesthesia, each rat experienced a skin incision to expose the skull in a supine position prior to the test. The probe was positioned 10 cm above the detected frontoparietal cortex region of the left hemisphere. A round window of approximately 0.8 mm$^2$ in size had been located below and to the left of the bregma, just adjacent to the MCA area. The cerebral blood flow perfusion color image (Figure 1D-1.a), detected position image Figure 1D-1.b), and blood flow time window (Figure 1D-1.d) were recorded. 

Reduced rate of rCBF = TOI1 – TOI2/TOI1 × 100%

Where the value of TOI1 and TOI2 were calculated as a percentage of the baseline value 15 min prior to and 30 min after the MCAO, respectively. YJ and EGb761 were administered intragastrically 15 min prior to MCAO.

2.11.5 Western blot analysis for apoptosis related protein-Cortex proteins. The rat brain homogenate in ice-cold lysis buffer containing 150 mM NaCl, 25 mM Tris–HCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% NP-40, 1 μg·ml$^{-1}$ aprotinin, 1 μg·ml$^{-1}$ leupeptin, and 1 mM PMSF, pH 7.4, was used for Western blot experiments [20%(w/v)]. The homogenate was incubated on ice for 30 min and then centrifuged at 12,000 rpm for 20 min at 4°C. The supernatant was collected, and the protein concentrations of the extracts were measured by BCA assay. The protein samples in the supernatant were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred to PVDF membranes [41]. The membrane was incubated with the respective primary antibodies against Bcl-2 (1:1000), Bax (1:1000) and activated caspase-3 (1:1000) overnight at 4°C. The antibody for β-actin (1:5000) served as the loading control. Finally, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody. Protein bands were visualized using the ECL Western blotting detection kit. The relative intensities of the bands were quantified by densitometric analysis. The densitometric plots of the results were normalized to the intensity of the actin band.

2.11.6 Western blot analysis for apoptosis related protein-Mitochondrial proteins. The release of mitochondrial cytochrome c was determined by Western blot experiments according to the method described by He [41]. The rat brain homogenate in ice-cold lysis buffer mentioned above [20% (w/v)] was centrifuged at 1000 rpm for 10 min, and the resulting supernatant was centrifuged at 10,000 rpm for 10 min. The pellet contained the mitochondrial fraction. The supernatant was then re-centrifuged at 10,000 rpm for 1 h at 4°C. The resulting supernatant was used as the cytosolic fraction. The forty microgram proteins in pellet and supernatant were prepared and immune blotted with cytochrome c antibody (1:1000). The relative intensities of the bands were also quantified by densitometric analysis. The densitometric plots of the results were normalized to the intensity of the actin band.

2.11.7 Morphological studies of mitochondria and brain tissue cells. Transmission electron microscopy was used to observe the ultrastructural changes of mitochondria and brain.
tissue cells. The sham, vehicle and YJ-treated (25 mg kg\(^{-1}\)) group rats were anesthetized, perfused with 0.9% NaCl (1000 ml kg\(^{-1}\)), and then perfusioned with 4% paraformaldehyde (1000 ml kg\(^{-1}\)) at 24 h after reperfusion. The parietal cortex was cut into 1 mm\(^3\), fixed with 2.5% glutaraldehyde for 2 h, and washed three times with PBS, 10 min once. Then the tissue was fixed with 1% osmic acid for 2 h, sequentially, washed with pure water, dehydrated with ethanol, replaced with propylene oxide and resin mixture, embedded in pure resin, and stained with uranyl acetate and lead citrate [60]. The cortical morphology was observed under H-7650 transmission electron microscope (Hitachi, Japan) and photographed.

2.11.8 Statistical analyses. The data were expressed as the mean ± SD. The statistical significance of the differences between groups was determined by one-way analysis of variance (ANOVA). \(P\) value <0.05 was considered statistically significant.

2.12 The study of the combination mechanisms of YJ

2.12.1 Measures of variable importance to indices. The main goal of this portion of the present study was to identify the influence of YJ on five indices that explain changes in the experimental data. In this work, the methodology used was the calculation of variable importance in the project (partial least squares) scores. The VIP statistic represents the influence on the responses of every predictor \(X\) value in the model. In fact, the VIP values reflect the importance of independent invariables in the predictive model with respect to \(Y\).

In this paper, the LARS-PLS model was developed to describe the quantitative relationship between the independent variables (\(X\)) and the response variables (\(Y\)). Based on the LARS-PLS model, the influence of the predictors by means of their importance in the prediction was investigated, according to the VIP score. The VIP score for the \(i^{th}\) variable was calculated as [61]:

\[
V_{IP_{Ai}} = \sqrt{\frac{1}{\sum_{a=1}^{p} \sum_{i=1}^{Q} \sum_{t=1}^{n} R_{t_{ij}}^{2}}} \left( \sum_{a=1}^{p} \sum_{i=1}^{Q} R_{t_{ij}}^{2} \right)^{w_{ai}^2}
\]

Where \(w_{ai}\) was the loading weight for variable \(j\) using component \(a\).

2.12.2 Synergistic experimental design. The formulae of TCM exhibited complex characteristics, which gave rise to difficulties in identifying the synergistic effect of each component. Based on the pharmacological experiment and uniform design experiment, we designed an experiment to prove whether the three components used together would demonstrate the maximum pharmacological effect.

In this experiment, two doses were used: 5 mg kg\(^{-1}\) and 25 mg kg\(^{-1}\). In each dose, three components, only one component and only two components were used, respectively. Fourteen experiments were conducted. More details are shown in Table 2.

Results

3.1 Multi-objective predictive models and optimal proportion of YJ on anti-cerebral ischemia efficacy

To better seek the mechanisms of action of the YJ, the quantitative data of several key indices about mitochondrial function were processed and integrated by data mining methods.

The multi-objective predictive analysis was performed by 3 factors and 5 indices as input variables for the uniform experimental data. We tried to fit the regression model based on the previous obtained nine samples. In total, four algorithms were used to build the computational model between drug components and medical indices, namely linear partial least squares (PLS) regression, multi-linear regression, Back-Propagation neural network regression (BPNN) and least angle regression-partial least squares (LARS-PLS) regression. Moreover, several indices were selected to evaluate the performance of each model to find the most suitable model for estimating target values.

Firstly, we compared the fitted value to the original data. As for each model, straight lines were plotted for the five medical indices to reveal the goodness of fitted values to the original data. The value of \(R^2\) was computed for each line, which measured fitting accuracy. In general, the value of \(R^2\) became closer to 1 when the points in the scatter plot moved closer to the straight line, indicating that the model fitted the original data more accurately. In cases of a perfect fit, all points fall on a straight line, and \(R^2 = 1\) accordingly. The values of \(R^2\) for the five medical indices were computed according to different computational models, shown in Figure 2A.

Through this comparison, it had been observed that the LARS-PLS regression model had the best performance among the four models. Considering that the number of samples was small, a slight change in the samples would affect the position of the plotted line. Thus, we sought other indices for further evaluation.

We plotted the predicted values of the four models on the same figure and compared their closeness with the original data. As was shown in Figure 2B, the four models achieved different performance in the five medical indices. Obviously, models, fitting the data more accurately, were more likely to decipher the inner mechanisms between the drug components and medical indices.

Based on these figures, we used two indices, namely the THILE Index and RMSE, to quantify the performance of the four models. The THILE Index was computed as

\[
\text{index} = \sqrt{\frac{1}{n} \sum_{i=1}^{n} (y_i - \bar{y})^2}
\]

where \(y_i\) was the original medical value and \(\bar{y}\) was the corresponding predicted value. Smaller THILE Index values indicated more accurate predictions; a perfect predictor’s THILE Index = 0. Considering that BPNN gave different predictions in different trials, we repeated it for ten times and took the average value as the performance of the neural network regression model (see Table S1).

As illustrated in the Supporting Information (Table S2), LARS-PLS was again demonstrated to obtain the best performance among the four models. The LARS-PLS model predicted the five target indices with the smallest THILE Index and RMSE values. The superiority of the LARS-PLS model could be divided to two aspects: the PLS algorithm had been validated to perform well in small sample cases, and LARS had been shown to improve the accuracy of the model by adding non-linear factors.

Thus, we chose the LARS-PLS model as the best predictor of the medical indices. Combined with the particle swarm optimization algorithm, the LARS-PLS model was used to find the optimal composition of the YJ. After searching the composition space using PSO, we sought the local optimal composition, illustrated in Table 3. The optimal proportion of the three components was approximately 3:2:0.5. The data, shown in Table 3, indicated that when the three drug components were given in this ratio, the five medical indices would be 429.8514,
4.0134, 24.6169, 0.1190, 104.0423 as the LARS-PLS prediction, respectively.

3.2 Validation of the optimal proportion of mitochondrial function

3.2.1 Measurement of mitochondrial vitality (Resazurin). Mitochondrial function was evaluated by measuring the fluorescence intensity of resorufin. As shown in Table 4, the mitochondrial viability was significantly reduced in the vehicle-treated group. This value decreased from 531.33 ± 61.53 to 330.28 ± 61.42 as a result of MCAO (P < 0.01). With the exception of the low-dose YJ group, the YJ-treated groups at doses of 5 mg·kg⁻¹ and 25 mg·kg⁻¹ and the EGb761-treated group at a dose of 4 mg·kg⁻¹ experienced greater improvements in mitochondrial function (P < 0.01) than the vehicle control.

3.2.2 Measurement of mitochondrial swelling (PT). Reduced OD at 520 nm indicated mitochondrial swelling. Mitochondrial swelling was more serious in the vehicle control compared to the sham group. The group treated with EGb761 and YJ (1 mg·kg⁻¹, 5 mg·kg⁻¹, and 25 mg·kg⁻¹) showed significantly (P < 0.01) reduced amounts of mitochondrial swelling (Table 4).

3.2.3 Mitochondrial membrane fluidity measurement (FP). Mitochondrial membrane fluidity was reflected by membrane viscosity (τ). A greater τ value indicated reduced fluidity of the mitochondrial membrane. As shown in Table 4, the vehicle-treated group had greater τ values (5.89 ± 3.11) compared to the sham group (P < 0.01). The τ values in the groups treated with EGb761 and YJ (1 mg·kg⁻¹, 5 mg·kg⁻¹, and 25 mg·kg⁻¹) were significantly less (P < 0.01) than that of the vehicle-treated group.

3.2.4 Measurement of Mitochondrial Transmembrane Potential (MMP, ΔΨm)—The method of rhodamine 123 (Rho). Changes in ΔΨm were monitored by measuring the release of rhodamine 123, which had been preloaded into mitochondria. As shown in Table 4, the ΔΨm were significantly decreased from 131.53 ± 2.23 mv to 125.17 ± 4.70 mv as a result of MCAO (P < 0.01). The EGb761-treated groups showed an enhanced membrane potential compared to the vehicle-treated group (P < 0.05). The YJ-treated groups showed an improved membrane potential (P < 0.05) at a dose of 25 mg·kg⁻¹. Treatment with YJ (5 mg·kg⁻¹) also led to improved membrane potential (P < 0.01). However, YJ at a dose of 1 mg·kg⁻¹ did not significantly improve the reduction in mitochondrial membrane potential.

3.2.5 Measurement of Mitochondrial Transmembrane Potential (MMP, ΔΨm)—The method of JC-1 (JC1). To measure the depolarization of the mitochondrial membrane, the mitochondrial membrane potential was measured with the JC-1 probe. The red/green fluorescence ratio of JC-1 was shown in Table 4. The vehicle-treated group had a significantly smaller ratio than the sham group; the ratio in the vehicle-treated group had greater τ values (0.589 ± 0.311) compared to the sham group (P < 0.01). The τ values in the groups treated with EGb761 and YJ (1 mg·kg⁻¹, 5 mg·kg⁻¹, and 25 mg·kg⁻¹) were significantly less (P < 0.01) than that of the vehicle-treated group.

Figure 5. The study of the combination mechanisms of YJ. (A-1) VIP score on linear PLS regression model. (A-2) VIP score on LARS-PLS regression model. (B). The principal component of mitochondrial function. (D). Effects of YJ on neurological deficits induced by MCAO. Values were expressed as the mean ± SD (n = 10), and the data were analyzed by one-way ANOVA. *P < 0.05 versus the sham group; **P < 0.01 versus the vehicle control. (C-1) The principal components of group G, GB, GJ and GBJ. *P < 0.01, **P < 0.05 versus the G-treated group. (C-2) The principal components of group B, GB, BJ and GBJ. *P < 0.01, **P < 0.05 versus the B-treated group. (C-3) The principal components of group J, BJ, GJ and GBJ. *P < 0.01, **P < 0.05 versus the J-treated group. doi:10.1371/journal.pone.0078902.g005
was reduced from 26.58±1.49 to 21.80±3.44 (P<0.01). The EGb761-treated group showed a significantly increased ratio (24.60±2.69; P<0.01) compared to the vehicle-treated group. At a dose of 25 mg kg⁻¹, YJ increased this ratio significantly (P<0.05); however, YJ at 1 mg kg⁻¹ and 5 mg kg⁻¹ did not significantly increase the ratio.

In conclusion, the YJ of the optimal proportions favored mitochondrial function at 24 h after MCAO. This suggested that the LARS-PLS regression model combined with PSO was relatively accurate in searching for the best ratio of components in the YJ.

3.3 The therapeutic effect of YJ with the optimal proportion

3.3.1 Neurological defects. Middle cerebral artery occlusion was performed on the left side, and 12 h/24 h following occlusion, right hind paresis was observed in rats compared to the contralateral side, as shown in Figure 1A. The mean neurological scores in the vehicle-treated groups were significantly (P<0.01) higher than the sham groups, indicating neurological defects after the MCAO both at 12 h and 24 h. In the EGb761-treated group and the YJ- (1 mg kg⁻¹, 5 mg kg⁻¹ and 25 mg kg⁻¹) treated groups, the neurological defects were significantly improved (P<0.01) or (P<0.05, at PM and AM) when compared to the vehicle-treated group at both 12 h and 24 h after MCAO.

3.3.2 Cerebral infarct size. At 12 h and 24 h after MCAO, the mean infarct volumes in the vehicle-treated group were 210.95±45.83 mm³ (P<0.01) and 239.06±46.72 mm³ (P<0.01), respectively (Figure 1B). Oral administration of EGb761 and YJ (1 mg kg⁻¹, 5 mg kg⁻¹, and 25 mg kg⁻¹) significantly reduced infarct volume (P<0.01) in these groups compared to the vehicle control group both at AM and PM.

3.3.3 Cerebral edema. Middle cerebral artery occlusion was performed on the left side, and the left brain was processed to evaluate the cerebral edema 12 h and 24 h after the occlusion. As shown in Figure 1C, at 12 h and 24 h after MCAO, the content of cerebral water in the vehicle-treated group (81.35±0.87, 12 h; 81.31±0.86, 24 h) was significantly (P<0.01) higher than that of the sham group. In the EGb761-treated groups, the content of cerebral water was significantly reduced (P<0.01) compared to the vehicle-treated group. At 24 h after MCAO, YJ at the 5 mg kg⁻¹ and 25 mg kg⁻¹ dosages improved cerebral edema significantly (P<0.01), both at AM and PM, compared to the vehicle-treated group. YJ at the dose of 1 mg kg⁻¹ could reduce the content of cerebral water at PM (P<0.05). At 12 h after MCAO, YJ at the 5 mg kg⁻¹ and 25 mg kg⁻¹ dosages improved cerebral edema significantly (P<0.01). However, the YJ- (1 mg kg⁻¹) treated group experienced no improvement in cerebral edema when compared to the vehicle-treated MCAO group.

3.3.4 Regional cortical blood perfusion. We detected the cerebral blood flow with using a Perfusion Speckle Imager (PERIMED, Sweden), and the picture is presented in Figure 1D-1. The reduction of cerebral blood flow following MCAO in the vehicle-treated group was (51.95±4.71)% compared to the sham group (P<0.01) (Figure 1D-2). The cerebral blood flows of the EGb761- and YJ- (1 mg kg⁻¹, 5 mg kg⁻¹ and 25 mg kg⁻¹) treated groups were significantly enhanced (P<0.01) compared to the vehicle-treated group after MCAO.

3.3.5 Evaluation of the Anti-apoptotic effect-Modulation of Bcl-2 and Bax Expression. As shown in Figure 3B, Bcl-2, a key protein that contributes to cell survival, was present in relatively high levels in the sham group; it was decreased in the vehicle control at 24 h after the MCAO. In contrast, the level of Bax, an important pro-apoptotic protein, increased markedly in the vehicle control. As shown in Figure 3C, the ratio of Bax/Bcl-2 in the vehicle control increased significantly (6.05-fold of sham); this may be involved in the apoptotic cell death caused by MCAO. In the dose range of 1–25 mg kg⁻¹, YJ reduced the up-regulation of Bax and increased the level of Bcl-2 when administered 6 h after MCAO. Therefore, treatment with YJ was effective in maintaining the balance between Bcl-2 and Bax.

3.3.6 Evaluation of the Anti-apoptotic effect-Modulation of Cytochrome c Expression. One of the mechanisms by which Bcl-2 blocks apoptosis is by decreasing cytochrome c release from mitochondria. As shown in Figure 3D, significant translocations of cytochrome c was detected in the vehicle control group, in which the ratio of cytochrome c content in the mitochondrial and cytosolic fractions was approximately 0.26-fold of the sham group (P<0.01) at 24 h after MCAO. YJ treatment markedly increased this ratio (P<0.01) (Figure 3D) when administered 6 h after the MCAO. These results suggested that YJ could significantly inhibit the release of cytochrome c.

3.3.7 Evaluation of the Anti-apoptotic effect-Modulation of activated Caspase-3 Expression. Caspase-3 is an important executioner in apoptosis because it hydrolyzes a number of structural and signaling proteins involved in this process. As illustrated in Figure 3E, Western blot analysis showed that the level of activated caspase-3 increased significantly after MCAO. However, there was a reduction of increased caspase-3 activation in the YJ- (1 mg kg⁻¹, 5 mg kg⁻¹ and 25 mg kg⁻¹) treated groups when YJ was administered 6 h after MCAO. The action of YJ with respect to these molecular events was most likely paralleled YJ’s effect on apoptosis [62].

3.3.8 Morphological studies of mitochondria and brain tissue cells. Morphological studies of mitochondria and brain tissue cells were illustrated in Figure 4. As shown in Figure 4A, neurons in sham-treated group had integrated structures. However, the nucleus of neurons was pyknosis and the organelles such as mitochondria were obviously damaged in the vehicle-treated group. Compared with the vehicle-treated group, the cellular morphology and the contents seemed to be improved in the YJ-treated (25 mg kg⁻¹) group. Mitochondrial morphologies were shown in Figure 4B. The mitochondrial cristae appeared tubular with regular intercristal cross-section and cristae junctions in the sham-treated group. Differently, the mitochondria in the vehicle-treated group were swelling in majority, the cristae were severely damaged and even dissolved. However, in the YJ-treated (25 mg kg⁻¹) group, the mitochondrial swelling was significantly reduced and the structure damage was significantly improved.

3.4 The study of the combination mechanisms of YJ

Considering the positive pharmacological effects of the YJ in optimal proportions, we made use of the VIP and synergistic experimental design to the further study of potential mechanisms of action of YJ.

3.4.1 Analysis of the importance of three compounds. VIP was used to measure the importance of each variable to interpret the variables. From the definitional formula of VIP, it is known that VIP is based on the PLSR model. In this paper, VIPs were computed by two PLSR models: the linear PLSR regression model and the LARS-PLS regression model. These models were used to analyze the data from the uniform design study to obtain the importance of each of the three components. The linear PLS VIP of the three components is shown in Figure 5A-1. In addition, the LARS-PLS VIP was took into account. Based on Lars, nine variables were generated: X1, X2, X3, X1×X1, X1, X1×X2, X2×X2, X1×X3, X2×X3, and X3×X3. The detailed VIP scores were shown in Figure 5A-2.
According to the results, showed in the linear PLS regression model and the LARS-PLS regression model, the VIP score indicated that J was more important than the other two components, and G was more important than B, which suggested that in the acute stage of MCAO, J played the most important role, even though it was just the component of the least concentration in the YJ.

3.4.2 Principal components analysis (PCA) to expose synergy effect of YJ. Principal components analysis (PCA) was used to analyze mitochondrial function to investigate the integrated effects of G, B and J. We extracted the principle component of the five mitochondrial indices. One-way ANOVA was used to analyze group differences. The principal component was illustrated in Figure 5B. The data from the vehicle-treated group (\(-0.91\pm0.20\)) was significantly \((P<0.01)\) less than that of the sham group, indicating greater mitochondrial dysfunction after MCAO. At doses of 5 mg\(\text{kg}^{-1}\) and 25 mg\(\text{kg}^{-1}\), the data of the GBJ group was significantly greater \((P<0.05\) and \(P<0.01\), respectively\) than that of vehicle-treated group. The data was also greater than the same dose of mono- or bi-therapy of G, B and J. The GBJ formulation showed strong synergy in preventing mitochondrial dysfunction at 24 h after MCAO. It was interesting that both at the doses of 5 mg\(\text{kg}^{-1}\) and 25 mg\(\text{kg}^{-1}\), BJ-treated groups had higher scores than the vehicle-treated group \((P<0.01)\). The scores of GB- and GJ-treated groups at doses of 5 mg\(\text{kg}^{-1}\) were not remarkably different than that of the vehicle-treated group. This suggested that at the acute stage of ischemic stroke, B and J played important roles in treatment.

Considering that at the 5 mg\(\text{kg}^{-1}\) dose the difference between drug-treated groups and vehicle-treated groups was not remarkable, 25 mg\(\text{kg}^{-1}\) treated group was used to conduct further analyses. As was shown in Figure 5 (C-1, C-2 and C-3), the synergy of GBJ was the strongest in our experiment. When G and J were added to B, the effect of B improved. It was interesting that J could improve the effect of B more than G, suggesting that a combination of B and J was better than any other bi-therapy. When G and B were added to J, they appeared different functions. B could improve the effect of J, but when G was combined with J, the interaction between G and J was reduced. The results showed that the synergy of GBJ was stronger than the interaction of G and B, G and J, and B and J. Among GB-, GJ- and BJ-treated groups, BJ performed the best.

3.4.3 Neurological defects verify the synergistic effect of YJ. As shown in Figure 5D, the mean neurological score in the vehicle-treated group \((2.20\pm0.42)\) was significantly \((P<0.01)\) higher than that of the sham group, indicating the presence of a neurological defect after MCAO. At the doses of 5 mg\(\text{kg}^{-1}\) and 25 mg\(\text{kg}^{-1}\), the scores of GBJ group were significantly lower \((P<0.01)\) than those of vehicle-treated group and groups receiving other treatment as the same dosage. It was interesting that at both the doses of 5 mg\(\text{kg}^{-1}\) and 25 mg\(\text{kg}^{-1}\), the BJ-treated groups obtained a lower score than the vehicle-treated group \((P<0.01)\). This was a result of the synergistic effect on mitochondrial function. It suggested that G, B and J were all indispensable components of the YJ, as indicated by synergy in the SD rats induced by MCAO.

Discussion

Recently, with the understanding of complex diseases growing, the focus of drug discovery research has shifted from the originally well-accepted “one target, one drug” model to a newer “multi-target, multi-drug” model that aims to systematically modulate multiple targets. The combination of multiple drugs is thought to maximize therapeutic efficacy by facilitating synergistic actions and ameliorating or preventing potential adverse effects, while at the same time, affecting multiple targets [63]. The change in new drug research and development provides an opportunity to develop TCM. TCM is based on a sophisticated system of medical theory and most traditional therapeutic formulæ consist of a combination of several drugs. They are great treasures for the development of combination drugs. Unfortunately, there is little evidence (including clinical data) that provides a strong scientific basis to justify mixing plant extracts to improve pharmacological efficacy in clinical treatment. But it must be noted that they do indeed exist [64,65]. The detailed action mechanisms of combination drugs from TCM stand out a major challenge. Moreover, the selection of the optimal combination and doses of ingredients in formulæ remains a matter of trial and error [66]. One of the major challenges of combination therapy and drug discovery is the lack of effective evaluation methods. Since the 1950s, data mining methods from mathematics, statistics, and other computational sciences have been gradually introduced into TCM studies, making this modality more scientific in nature. Meanwhile, the distinct features of TCM theories and diagnostic model have constantly promoted the development of statistical methodologies [67].

Correct target identification and subsequent pharmacological manipulation of targets may give great help in the prevention and/or treatment of a number of the most prevalent diseases, including neurodegenerative disorders [68]. Strategies to antagonize injurious biochemical and molecular events that eventuate in irreversible injury in ischemic stroke are required [69]. Recanalization and neuroprotection are the two major approaches used to treat ischemic stroke. Considering the limitations related to its narrow therapeutic time window and concerns of hemorrhagic conversion, thrombolysis with a tissue plasminogen activator (tPA) is limited [8]. It is inevitable that thrombolysis must be evaluated clinically in combination with neuroprotectant agents. Based on the symptoms and characteristics of ischemic stroke patients and guided by TCM theories, formulæ are designed to contain a combination of different types of plants or minerals to improve the clinical efficacy of treatment. It may be possible to find a combination of vasoactive drugs and neuroprotective agents in TCM formulæ.

In the last decade, mitochondria have provided a vast area of research in pharmacology; a wealth of potential targets for drug action had been identified. A large body of research has demonstrated that MCAO induces marked mitochondrial dysfunction, including mitochondrial transition pore opening, membrane potential depolarization, and so on. Protection of mitochondrial function is closely related to stroke treatment [70–72]. In this study, we made use of mitochondrial function to evaluate the integrated effect and related mechanism of YJ on the treatment of acute ischemic stroke.

There may be an optimal proportion of formulaic ingredients to produce the best pharmacological action. To seek it, a new multi-objective regression algorithm was proposed based on LARS-PLS to construct the predictive model of pharmacological activity of YJ. Additionally, the optimal proportion of three compounds was found to be 3 (G): 2 (B): 0.5 (J), which was determined by PSO based on the predictive model mentioned above. Due to the limit of pharmacological experiments, it is hard to perform more than ten groups simultaneously, which means that the size of samples for further analysis is extremely small. When mathematical models were applied to it, it is easy to over fit the small data. Furthermore, a pharmacological index is computed as mean value of several
(usually more than six) animals. Generally speaking, for small size data, the fitting accuracy is nearly 100%, but the predictive performance is sometimes notorious. In order to avoid this, we used two strategies. The one is to use LARS associated algorithm to deal with this small size data. The other is to sacrifice some fitting accuracy in order to compensate some predictive accuracy. The successful application of these two strategies provided a strong basis for multi-objective optimization here [73,74].

To verify the precision of our predictive model, we conducted a confirmatory experiment of the effect of YJ. In this experiment, YJ obviously favored the improvement of mitochondrial structure and function, as indicated by the attenuation of mitochondrial swelling and membrane viscosity, amelioration of the reduced mitochondrial membrane potential state, and inhibition of cerebral ischemia-induced mitochondrial dysfunction at 24 h after MCAO. To clarify whether YJ in the optimal 3:2:0.5 proportion could exhibit significant pharmacological effects on acute ischemic stroke, we further determined the accuracy of the predictive model. We performed the pharmacological experiments both in animal models and the molecular level. It is common sense that cerebral ischemia can cause brain injury that may leading to neurology defects, cerebral infarction and neuronal death by apoptosis and/or necrosis [75]. Our results indicated that YJ at doses of 1, 5 and 25 mg kg\(^{-1}\) exhibited significant anti-cerebral ischemia activity at 12 h and 24 h after focal cerebral ischemia in a MCAO rat model, both at PM and AM. We demonstrated that YJ reduces infarct volumes after cerebral ischemic injury. Protection appeared in the early stage of acute ischemic stroke, and it is associated with improvement of the neurological deficits and cerebral edema resulting from arterial occlusion at PM and AM. Cerebral blood flow (CBF) derangements play key roles in the development of brain damage following cerebral ischemia [76]. Therefore, improved CBF has been proposed as one of the main strategies to limit ischemic injury [77]. Intriguingly, after YJ was administrated, there was a remarkable improvement in rCBF after focal cerebral ischemia in a MCAO rat model, both at PM and AM. We demonstrated that YJ could improve the injuried mitochondrial and neuronic morphol-

Mitochondria play a key role in many apoptotic cascades and apoptotic cell death [78]. The mitochondrial pathway is closely associated with cell injury in cerebral ischemia. Following mitochondrial protection, YJ sequentially inhibits caspase-dependent (cytochrome c and caspase-3) mitochondrial cell death pathways. In the caspase-dependent manner, the release of cytochrome c activates the caspase cascade [4]. YJ at doses of 1, 5 and 25 mg kg\(^{-1}\) inhibited the activation of caspase-3, decreased Bax expression, increased Bcl-2 expression and maintained the balance of pro- and anti-apoptotic proteins at 24 h after MCAO. Moreover, the markedly reduced release of cytochrome c from mitochondria as a result of YJ after the MCAO was also detected. Furthermore, ultrastructure observation results showed that YJ could improve the injured mitochondrial and neuronic morphologies at the dose of 25 mg kg\(^{-1}\).

So far, we proposed the three components and the optimal proportion of these components in YJ as a combination drug for the first time with the assistance of mathematical methods. Given that the YJ performed so well in terms of pharmacodynamics, we introduced the PLS VIP and synergistic experimental designs to explore the potential combination mechanism. The results of the PLS VIP suggested that J was the most important component in the formula. The principal components analysis results showed that the G, B and J combination could exhibit the strongest integrated pharmacological effect among all other possible combinations, suggesting that the three components are all indispensable. Among the mono- or bi-therapy combinations of G, B and J, B combined with J performed best. B, an isoquinoline alkaloid extracted from medicinal herbs, has been historically used as an antipyretic, anti diarrheal, bactericide and anti-inflammatory agent [79]. Recently, it has been reported that B has multiple neuropharmacological properties, such as anti-neuronal apoptosis effects [80]. The effect of J is manifested as detoxification, which can repair damage to vascular endothelial cells and block the progression of cascading damage observed in cerebral ischemia [81]. G is a tonic, which could improve the overall state of the organism. Abundant literature has revealed that G could alleviate many central nervous system disorders, including ischemic stroke [82]. Though J was only in small amounts in YJ, our data indicated that J was the key component of this formula. J counteracted the cardinal pathological effects of acute ischemic stroke. All of these results indicated that in the treatment of acute ischemic stroke, we should pay more attention to the removal of the toxic metabolites.

Supporting Information

**Figure S1** The chromatogram of Rb2. (TIF)

**Figure S2** The chromatogram of Rd. (TIF)

**Figure S3** The chromatogram of Re. (TIF)

**Figure S4** The chromatogram of Rg1. (TIF)
Figure S5  The chromatogram of test sample solution (20110510).
(TIF)
Figure S6  The chromatogram of test sample solution (20110530).
(TIF)
Figure S7  The chromatogram of test sample solution (20110612).
(TIF)
Figure S8  The chromatogram of Rb1.
(TIF)
Figure S9  The chromatogram of Rb3.
(TIF)
Figure S10  The chromatogram of Rc.
(TIF)
Figure S11  The chromatogram of F1.
(TIF)
Figure S12  The chromatogram of F2.
(TIF)
Figure S13  The chromatogram of Rg3.
(TIF)
Figure S14  The chromatogram of test sample solution (20110510).
(TIF)
Figure S15  The chromatogram of test sample solution (20110530).
(TIF)
Figure S16  The chromatogram of test sample solution (20110612).
(TIF)
Figure S17  The mass spectrum of the Rg1 solution and the test sample solution. a. Rg1; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S18  The mass spectrum of the Re solution and the test sample solution. a. Re; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S19  The mass spectrum of the Rd solution and the test sample solution. a. Rd; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S20  The mass spectrum of the Rb1 solution and the test sample solution. a. Rb1; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S21  The mass spectrum of the Rb2 solution and the test sample solution. a. Rb2; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S22  The mass spectrum of the Rb3 solution and the test sample solution. a. Rb3; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S23  The mass spectrum of the F1 solution and the test sample solution. a. F1; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S24  The mass spectrum of the F2 solution and the test sample solution. a. F2; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S25  The mass spectrum of the Rc solution and the test sample solution. a. Rc; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)
Figure S26  The mass spectrum of the Rg3 solution and the test sample solution. a. Rg3; b. the batch of 20110510; c. the batch of 20110530; d. the batch of 20110612.
(TIF)

Text S1  Supporting Information Legends.
(DOC)

Table S1 THILE Index and RMSE for BPNN regression model.
(TIF)
Table S2 Comparison of THILE Index and RMSE among the four models.
(TIF)
Table S3 The peak area of each ginsenosides standards.
(TIF)
Table S4 The peak area of each ginsenosides standards in three batches.
(TIF)
Table S5 The content of each ginsenosides standards in three batches.
(TIF)

Author Contributions
Conceived and designed the experiments: SL CW JC HY. Performed the experiments: CW CC JG LZ RL XS. Analyzed the data: JC PL. Contributed reagents/materials/analysis tools: MF JF. Wrote the paper: SL CW JC.

References
1. Xutian S, Zhang J, Louise W (2009) New exploration and understanding of traditional Chinese medicine. Am. J. Chin. Med. 37: 411-426.
2. Li S, Zhang B, Zhang N (2011) Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC. Syst. Biol. 5 Suppl 1: S10.
3. Wang L, Zhou GB, Liu P, Song JH, Liang Y, et al. (2008) Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 105: 4026-4031.
4. Vosler PS, Graham SH, Wechsler LR, Chen J (2009) Mitochondrial targets for stroke: focusing basic science research toward development of clinically translatable therapeutics. Stroke. 40: 3149-3155.
5. Kamaan K, Holcombe RF, Jain SK, Alvarez-Hernandez X, Chervenak R, et al. (2000) Evidence for the induction of apoptosis by endosulfan in a human T-cell leukemia line. Mol. Cell. Biochem. 205: 53-66.
6. Bloemgren K, Zhu C, Hallin U, Hagberg H (2003) Mitochondria and ischemic reperfusion damage in the adult and in the developing brain. Biochem. Biophys. Res. Commun. 304: 551-559.
7. Sims NR, Anderson MF (2002) Mitochondrial contributions to tissue damage in stroke. Neurosci. Res. Commun. 30: 511-526.
37. Tian J, Fu F, Geng M, Jiang Y, Yang J, et al. (2005) Neuroprotective effect of
36. Zhang HX, Du GH, Zhang JT (2004) Assay of mitochondrial functions by
35. Jiang WL, Zhang SP, Zhu HB, Hou J, Tian JW (2010) Cornin ameliorates
34. Zhang X, Zhang X, Wang C, Li Y, Dong L, et al. (2012) Neuroprotection of
33. Kuo WH, Wang CJ, Young SC, Sun YC, Chen YJ, et al. (2004) Differential
32. Suzuki Y, Kondo K, Ikeda Y, Umemura K (2001) Antithrombotic effect of
31. Umetrics AB (2006) Multi- and Megavariate Data Analysis, part 1, Basic
30. Shi LL, Chen BN, Gao M, Zhang HA, Li YJ, et al. (2011) The characteristics of
therapeutic effect of pinitocerin in transient global brain ischemia/reperfusion
rat model Neurochem Res 36: 192–197.
29. Chen LM, Zhou XM, Cao YL, Hu WX (2008) Neuroprotection of ginsenoside
28. Sucher NJ (2006) Insights from molecular investigations of traditional Chinese
27. Gertsch J (2011) Botanical drugs, synergy, and network pharmacology: forth and
26. Braun DA, Duma AK (2010) Laser speckle contrast imaging in biomedical optics.
25. Dragstedt RW, Swanson DL, Gray JH, Donley DR, Layton KA (1975) The
24. Kennedy J, Eberhart RC (1995) Particle swarm optimization, in Proc. IEEE Int.
23. Zhou XM, Cao YL, Dou DQ (2006) Protective effect of ginsenoside-Re against
22. Koo HJ, Lee S, Shin KH, Kim BC, Lim CJ, et al. (2004) Geniposide, anti-
21. Zhang X, Zhang X, Wang C, Li Y, Dong L, et al. (2012) Neuroprotection of
20. Koo WH, Wang CJ, Young SC, Sun YC, Chen YJ, et al. (2004) Differential
19. Jiang WL, Zhang SP, Zhu HB, Hou J, Tian JW (2010) Cornin ameliorates
18. Liu J, Yin F, Xiao H, Guo L, Gao X (2012) Glucagon-like peptide 1 receptor plays
17. Zhou XM, Cao YL, Dou DQ (2006) Protective effect of ginsenoside-Re against
16. Koo WH, Wang CJ, Young SC, Sun YC, Chen YJ, et al. (2004) Differential
15. Zheng GQ, Cheng W, Wang Y, Wang XM, Zhao SZ, et al. (2011) Ginseng total
14. Radal K, Moldrů K, Rauch WD (2011) Ginsenosides and their CNS targets.
13. Nakaya Y, Mawatari K, Takahashi A, Harada N, Hata A, et al. (2007) The
12. Yang L, Xu S, Liu C, Su Z (2009) In vivo metabolism study of ginsenoside Re in
11. Lindvall O, Kokaia Z (2004) Recovery and rehabilitation in stroke: stem cells.
10. Nakaya Y, Mawatari K, Takahashi A, Harada N, Hata A, et al. (2007) The
9. Hata R, Mies G, Wiessner C, Fritze K, Hesselbarth D, et al. (1998) A
8. Lin CY, Wu HY, Wang ML, Wu HC, Chen YJ, et al. (2004) Protective effect of
cascades of damage of cerebral ischemia in rats. Zhongguo Zhong Yao Za
7. Koo HJ, Lee S, Shin KH, Kim BC, Lim CJ, et al. (2004) Geniposide, anti-
6. Shi LL, Chen BN, Gao M, Zhang HA, Li YJ, et al. (2011) The characteristics of
5. Huang J, Tang L, Wang R, Wang J, Yu P, et al. (2012) Protective effects of
cerebral ischemia/reperfusion injury in rats. J Asian Nat Prod Res. 10: 531–538.
4. Peng J, Peng Y, Ouyang LN (2008) Hybrid particle swarm optimization and
3. Bove SA, van der Graaf PH, Voskuyl RA, Danhof M (2005) Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmaco Ther. 105: 1–18.
2. Ho J, Qiao J, Kang D, Liu B (2011) Analysis on the distinguishing features of traditional Chinese therapeutics and related statistical issues. Front Med. 5: 203–207.
1. Chen J, Zhao H, Yang Y, Liu B, Ni J, et al. (2011) Lipid-lowering and antiplatelet activities of Jiaogulan-Yang in Traditional Chinese Medicine. J Ethnopharmacol. 134: 919–926.
70. Dave KR, DeFazio RA, Raval AP, Torracco A, Saul I, et al. (2008) Ischemic preconditioning targets the respiration of synaptic mitochondria via protein kinase C epsilon. J Neurosci. 28: 4172–4182.
71. Zheng CY, Zhang HY, Tang XC (2008) Huperzine A attenuates mitochondrial dysfunction after middle cerebral artery occlusion in rats. J Neurosci Res. 86: 2432–2440.
72. Shen H, Kuo CC, Chou J, Deolve A, Jackson SN, et al. (2009) Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 23: 1958–1966.
73. Yang HJ, Chen JX, Tang SH, Li ZK, Zhen YS, et al. (2009) New drug R&D of traditional Chinese medicine: Role of data mining approaches. Journal of Biological Systems. 17: 329–347.
74. Chen C, Chen JX, Wu HW, Tang SH, Li G, et al. (2011) Identification of key constituents in volatile oil of ligusticum chuanxiong based on data mining approaches. Pharmaceutical Biology, 49: 445.
75. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, et al. (2007) Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol. 566: 153–159.
76. Rudziński W, Szwat M, Tomaszewski M, Krófa J (2007) Cerebral hemodynamics and investigations of cerebral blood flow regulation. Nucl Med Rev Cent East Eur. 10: 29–42.
77. Della Morte D, Rave AP, Dave KR, Lin HW, Perez Pinzon MA (2011) Post-Ischemic Activation of protein kinase C epsilon protects the hippocampus from cerebral ischemic injury via alterations in cerebral blood flow. Neurosci Lett. 487: 158–162.
78. Everett H, Barry M, Sun X, Lee SF, Frantz C, et al. (2002) The myxoma poxvirus protein, M11L, prevents apoptosis by direct interaction with the mitochondrial permeability transition pore. J Exp Med. 196: 1127–1139.
79. Benaissa F, Mohseni Rad H, Rahimi Moghaddam P, Mahmoushian M (2009) Berberine reduces the hypoxic-ischemic insult in rat pup brain. Acta Physiol Hung. 96: 213–220.
80. Ye M, Fu S, Pi R, He F (2009) Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J Pharm Pharmacol. 61: 831–837.
81. Zhang G, He J, Xie X, Yu C (2012) LPS-induced iNOS expression in N9 microglial cells is suppressed by ginsenoside via ERK, p38 and nuclear factor-κB signaling pathways. Int J Mol Med. 30: 561–568.
82. Lu T, Jiang Y, Zhou Z, Yue X, Wei N, et al. (2011) Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats. Biol Pharm Bull. 34: 1319–1324.
83. Koh PO (2011) Ginseng biloba extract (EGb 761) attenuates the focal cerebral ischemic injury-induced decrease in astrocytic phosphoprotein PEA-15 levels. Am J Chin Med. 39: 971–979.
84. Zhang Z, Peng D, Zhu H, Wang X (2012) Experimental evidence of Ginkgo biloba extract EGB as a neuroprotective agent in ischemia stroke rats. Brain Res Bull. 87: 193–199.
85. Shi C, Xiao S, Liu J, Guo K, Wu F, et al. (2010) Ginkgo biloba extract EGB761 protects against aging-associated mitochondrial dysfunction in platelets and hippocampi of SAMP8 mice. Platelets. 21: 373–379.
86. Shen J, Lee W, Gu Y, Tong Y, Fung PC, et al. (2011) Ginkgo biloba extract (EGb761) inhibits mitochondria-dependent caspase pathway and prevents apoptosis in hypoxia-reoxygenated cardiomyocytes. Chin. Med. 6: 8.